PF-Atlas › Clinical Trials › NCT03219164
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
AZLI · Phase 3
Registry ID
NCT03219164
Phase
Phase 3
Status
Terminated
Drug / intervention
AZLI
Sponsor
Gilead Sciences
Start
2017-11-28
About this trial
AZLI is evaluated in NCT03219164, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Gilead Sciences. Current status: Terminated.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03219164 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.